The liraglutide arm had significantly greater %-Estimated weight loss (liraglutide: 58.7% %EWL, placebo: 44.5%, p = 0.043) and resolution of dysglycaemia (liraglutide: 100% resolution, Placebo: 50%) than placebo
For weight management, the proportion of individuals with overweight or obesity achieving 5% weight loss increases (approximately equivalent to 25 kg, depending on baseline weight), a threshold associated with improvements in blood pressure, blood lipids, functional capacity, and health-related quality of life 48
What sets tirzepatide apart is its dual-action mechanism: it activates both the GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors two natural hormones that regulate appetite and blood sugar levels
No injections, no controlled substance restrictions, no hormonal manipulation